Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
Amphista Therapeutics announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone. The collaboration and license agreement with Bristol Myers Squibb was announced on May 4, 2022 and included a $30 million upfront payment, the potential for up to $1.25 billion in performance-based milestone payments and payment for a limited expansion of the collaboration, as well as royalties on global net sales of products. Amphista is responsible for the discovery and development of small molecule protein degraders using Eclipsys
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
